# A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults

> **NCT01399788** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 36 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Myrin P Forte
- **DRUG:** Single drug references

## Key facts

- **NCT ID:** NCT01399788
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01399788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01399788, "A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01399788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*